<unk>  is a medication used for the treatment of type 2 diabetes or obesity. Type 2 diabetes<unk>  improves control of blood glucose. As of 2017 it is unclear if incretin mimetics like<unk>  affect a person's risk of death. In diabetes it is a less preferred agent. It may be used in those in who metformin and another antidiabetic medication such as a sulfonylurea are not sufficient. A 2011 Cochrane review showed a HbA1c reduction of 0.24% more with<unk>  1.8mg compared to insulin glargine, 0.33% more than exenatide 10µg twice daily, sitagliptin and rosiglitazone. Obesity<unk>  may also be used together with diet and exercise for chronic weight management in adult patients.<unk>  has been shown to lead to greater weight loss than other glucagon-like peptide analogues. The body mass index (BMI) needs to be greater than 30 kg/m2, or greater than 27 kg/m2 together with high blood pressure, type 2 diabetes mellitus, or dyslipidemia. It is unknown if the weight loss will be permanent. Appetite suppression may be temporary and appetite might return even if one continues to use<unk>  after 56 weeks.
Liraglutide
Exenatide
Linagliptin
Pioglitazone
Vildagliptin
Canagliflozin
Rosiglitazone
Sitagliptin